LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$30.48 USD
+1.15 (3.92%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $30.47 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
LENZ Therapeutics, Inc.'s return on equity, or ROE, is -25.63% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that LENZ has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
LENZ 30.48 +1.15(3.92%)
Will LENZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LENZ
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
LENZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Other News for LENZ
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
Lenz Therapeutics price target raised by $9 at BofA, here's why
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
Lenz Therapeutics price target raised by $8 at H.C. Wainwright, here's why